secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001689548-24-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Q3 net loss $51.9M; relutrigine seizure freedom; ulixacaltamide interim Q1 2025
--------------------------------------------------------------------------------

- Cash and equivalents $411.2M at Sep 30, 2024, up from $81.3M at Dec 31, 2023; net loss $51.9M vs $24.6M prior year Q3.
- Relutrigine (PRAX-562): 46% placebo-adjusted seizure reduction in EMBOLD cohort 1; 30% of patients (5/15) achieved seizure freedom; registrational cohort 2 initiated.
- Ulixacaltamide: interim analysis for Phase 3 Essential3 Study 1 expected Q1 2025; NDA filing anticipated in 2025; Parkinson's program to re-initiate.
- Vormatrigine (PRAX-628): RADIANT topline in H1 2025 and POWER1 topline in H2 2025; pain expansion being evaluated.
- R&D expenses $41.9M (up $24.6M); G&A $15.3M (up $6.6M); stock-based compensation $12.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/0001689548-24-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000098/prax-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer